Lexeo Therapeutics Inc

LXEO remains in a clear Stage 4 decline with persistent lower highs and lower lows below its major moving averages, confirming medium-term bearish bias. An active Lower Highs & Lower Lows pattern indicates supply dominance, while a short-term rally into the 9/21 EMA zone has improved ST trend but offers no durable reversal. Execution is deferred: wait for a stronger rally toward the 50 DMA before trimming exposure. A decisive failure back below the 9/21 EMAs would reinvigorate bearish conviction.

• ↑Pipeline targets rare diseases; clinical updates due at Sep 2 investor conferences
• ↑13F ownership above 4 indicates strong hedge fund interest and support
• ↓Negative earnings yield (-3.46%) and weak profitability signal poor returns